6533b85afe1ef96bd12b95d4
RESEARCH PRODUCT
Anti-angiogenic therapies in prostate cancer.
José María Martínez-jabaloyasMaría Mercedes Navarro-garcíaFrancisco DasíJ.a. March-villalbasubject
PharmacologyOncologyMalePathologymedicine.medical_specialtyEvidence-Based Medicinebusiness.industryAngiogenesisClinical BiochemistryAnti angiogenicCancerProstatic NeoplasmsAngiogenesis InhibitorsEvidence-based medicineurologic and male genital diseasesmedicine.diseaseClinical trialProstate cancerClinical evidenceInternal medicineDrug DiscoverymedicineHumansbusinessdescription
Prostate cancer (PCa) is the second most common type of cancer among men in Western societies. Once in the castrate-resistant metastatic setting therapeutic options are limited. The importance of angiogenesis in the progression of PCa has been widely reported providing a rationale to test anti-angiogenic compounds for PCa treatment in clinical trials (CTs). However, in spite of the promising results shown in preclinical models and some anti-tumor activity observed in CTs, to date, no angiogenic inhibitor has been approved for use in PCa. This editorial outlines the latest clinical evidence regarding anti-angiogenic therapies in PCa treatment.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2012-10-24 | Expert opinion on biological therapy |